DDIT3 and non-Hodgkin lymphoma: Some patients (27%) were extensively pretreated: 5 cycles of B-ALL/NHL regimen of the German ALL study group [44] (rituximab, cyclophosphamide, methotrexate, vindesine, etoposide, doxorubicin, cytarabine); 6 cycles of R-mini-CHOP [21] + 6 cycles R-TPIP (rituximab, trofosfamide, procarbazine, idarubicin, prednisone); 6 cycles R-CHOP + 14 × rituximab maintenance.